These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21275826)

  • 1. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.
    Wang T; Kulkarni N; Bedi D; D'Souza GG; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
    J Drug Target; 2011 Sep; 19(8):597-605. PubMed ID: 21275826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence matters.
    Wang T; Kulkarni N; D'Souza GG; Petrenko VA; Torchilin VP
    Mol Pharm; 2011 Oct; 8(5):1720-8. PubMed ID: 21675738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a liposomal formulation of the natural flavonoid fisetin.
    Mignet N; Seguin J; Ramos Romano M; Brullé L; Touil YS; Scherman D; Bessodes M; Chabot GG
    Int J Pharm; 2012 Feb; 423(1):69-76. PubMed ID: 21571054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.
    Wang T; D'Souza GG; Bedi D; Fagbohun OA; Potturi LP; Papahadjopoulos-Sternberg B; Petrenko VA; Torchilin VP
    Nanomedicine (Lond); 2010 Jun; 5(4):563-74. PubMed ID: 20528452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
    Herringson TP; Altin JG
    J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
    Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y
    J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
    Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
    J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chondroitin sulfate functionalized liposomes for solid tumor targeting.
    Bagari R; Bansal D; Gulbake A; Jain A; Soni V; Jain SK
    J Drug Target; 2011 May; 19(4):251-7. PubMed ID: 20545459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melittin liposomes surface modified with poloxamer 188: in vitro characterization and in vivo evaluation.
    Tian JL; Ke X; Chen Z; Wang CJ; Zhang Y; Zhong TC
    Pharmazie; 2011 May; 66(5):362-7. PubMed ID: 21699070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
    Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
    Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
    Dadashzadeh S; Vali AM; Rezaie M
    Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
    Padamwar MN; Pokharkar VB
    Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
    J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
    Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
    J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
    Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
    Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.